Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease

Zhongguo Zhongyao Zazhi

Volumn 36, Issue 21, 2011, Pages 3032-3035

  Xie, Xiaoming ^a   Meng, Xiaojun ^a   Zhou, Xiaojun ^a   Shu, Xiaochun ^a   Kong, Hongjuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Berberine; Hemorheology; Nonalcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BERBERINE; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; XUEZHIKANG;

ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RANDOMIZATION; THERAPY EFFECT;

ADULT; ALANINE TRANSAMINASE; BERBERINE; DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FATTY LIVER; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84862936629     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20112127     Document Type: Article

References (9)

1. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact[J]. Clin Gastroenterol Hepatol, 2004, 2:1048.
2. Hanley A J, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome the insulin resistance atherosclerosis study[J]. Diabetes, 2005, 54:3140.
3. Zelle D M, Corpeleijn E, van Ree R M, et al. Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients [J]. Am J Transplant, 2010, 10:106.
4. Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL[J]. Fundam Clin Pharmacol, 2009, 23(6):681.